Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Ohmi, Yuhsuke ^a   Ohkawa, Yuki ^a   Tajima, Orie ^b   Sugiura, Yasuo ^a   Furukawa, Keiko ^a,b   Furukawa, Koichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GANGLIOSIDE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ALPHA-N-ACETYLNEURAMINATE ALPHA-2,8-SIALYLTRANSFERASE; BETA-1,4-N-ACETYL-GALACTOSAMINYL TRANSFERASE 1, MOUSE; COMPLEMENT COMPONENT C3; DIFFERENTIATION ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOLIPID; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; N ACETYLGALACTOSAMINYLTRANSFERASE; SIALYLTRANSFERASE;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; C1QALPHA GENE; C3AR GENE; C4 GENE; C5 GENE; C5AR GENE; CELL COUNT; CELL PROLIFERATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FOOTPRINT TEST; GAIT; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; GM2 GANGLIOSIDOSIS; KNOCKOUT MOUSE; LIPID ANALYSIS; MALE; MICROGLIA; MOTONEURON; MOUSE; MYELITIS; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; UPREGULATION; VON FREY TEST; WILD TYPE; ANIMAL; DEFICIENCY; DEGENERATIVE DISEASE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; INFLAMMATION; METABOLISM; PAIN MEASUREMENT; PATHOLOGY; PATHOPHYSIOLOGY; THIN LAYER CHROMATOGRAPHY;

ANIMALS; ANTIGENS, DIFFERENTIATION; CHROMATOGRAPHY, THIN LAYER; COMPLEMENT C3; CYTOKINES; DISEASE MODELS, ANIMAL; GANGLIOSIDES; GENE EXPRESSION PROFILING; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOLIPIDS; INFLAMMATION; MICE; MICE, KNOCKOUT; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEURODEGENERATIVE DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAIN MEASUREMENT; SIALYLTRANSFERASES; SPINAL CORD;

EID: 84897370994     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-61     Document Type: Article

References (57)

1. Schengrund CL. The role(s) of gangliosides in neural differentiation and repair: a perspective. Brain Res Bull 1990, 24:131-141. 10.1016/0361-9230(90)90297-D, 2178726.
2. Furukawa K, Tokuda N, Okuda T, Tajima O. Glycosphingolipids in engineered mice: insights into function. Semin Cell Dev Biol 2004, 15:389-396. 10.1016/j.semcdb.2004.03.006, 15207829.
3. Furukawa K, Tajima O, Okuda T, Tokuda N, Furukawa K. Knockout mice and glycolipids. Comprehensive Glycoscience from Chemistry to Systems Biology 2007, 149-157. Oxford, UK: Elsevier, Kamerling JP, Boons GJ, Lee YC, Suzuki A, Taniguchi N, Voragen AG.
4. Kittaka D, Itoh M, Ohmi Y, Kondo Y, Fukumoto S, Urano T, Tajima O, Furukawa K. Impaired hypoglossal nerve regeneration in mutant mice lacking complex gangliosides: down-regulation of neurotrophic factors and receptors as possible mechanisms. Glycobiology 2008, 18:509-516. 10.1093/glycob/cwn032, 18480155.
5. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, Fukumoto S, Haraguchi M, Takeda N, Fujimura K, Sakae M, Kishikawa M, Shiku H, Furukawa K, Aizawa S. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci U S A 1996, 93:10662-10667. 10.1073/pnas.93.20.10662, 38211, 8855236.
6. Sheikh KA, Sun J, Liu Y, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci U S A 1999, 96:7532-7537. 10.1073/pnas.96.13.7532, 22120, 10377449.
7. Sugiura Y, Furukawa K, Tajima O, Mii S, Honda T. Sensory nerve-dominant nerve degeneration and remodeling in the mutant mice lacking complex gangliosides. Neuroscience 2005, 135:1167-1178. 10.1016/j.neuroscience.2005.07.035, 16165298.
8. Okada M, Itoh Mi M, Haraguchi M, Okajima T, Inoue M, Oishi H, Matsuda Y, Iwamoto T, Kawano T, Fukumoto S. b-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. J Biol Chem 2002, 277:1633-1636. 10.1074/jbc.C100395200, 11682464.
9. Inoue M, Fujii Y, Furukawa K, Okada M, Okumura K, Hayakawa T, Sugiura Y. Refractory skin injury in complex knock-out mice expressing only the GM3 ganglioside. J Biol Chem 2002, 277:29881-29888. 10.1074/jbc.M201631200, 12023957.
10. Tajima O, Egashira N, Ohmi Y, Fukue Y, Mishima K, Iwasaki K, Fujiwara M, Inokuchi J, Sugiura Y, Furukawa K. Reduced motor and sensory functions and emotional response in GM3-only mice: emergence from early stage of life and exacerbation with aging. Behav Brain Res 2009, 198:74-82. 10.1016/j.bbr.2008.10.024, 19013484.
11. Kawai H, Allende ML, Wada R, Kono M, Sango K, Deng C, Miyakawa T, Crawley JN, Werth N, Bierfreund U, Sandhoff K, Proia RL. Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. J Biol Chem 2001, 276:6885-6888. 10.1074/jbc.C000847200, 11133999.
12. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 1999, 96:9142-9147. 10.1073/pnas.96.16.9142, 17746, 10430909.
13. Jennemann R, Sandhoff R, Wang S, Kiss E, Gretz N, Zuliani C, Martin-Villalba A, Jäger R, Schorle H, Kenzelmann M, Bonrouhi M, Wiegandt H, Gröne HJ. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci U S A 2005, 102:12459-12464. 10.1073/pnas.0500893102, 1194904, 16109770.
14. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 1998, 33:371-378. 10.1016/S0531-5565(98)00013-8, 9762518.
15. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1992, 89:10016-10020. 10.1073/pnas.89.21.10016, 50268, 1438191.
16. Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, Goux WJ, Lee V, Johnson GV, Webster SD, Cooper NR, Bradt B, Rogers J. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 2001, 305:165-168. 10.1016/S0304-3940(01)01842-0, 11403931.
17. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol 2011, 48:1592-1603. 10.1016/j.molimm.2011.04.003, 3142281, 21546088.
18. Brennan FH, Anderson AJ, Taylor SM, Woodruff TM, Ruitenberg MJ. Complement activation in the injured central nervous system: another dual-edged sword?. J Neuroinflammation 2012, 9:137. 10.1186/1742-2094-9-137, 3464784, 22721265.
19. Master protocol details. http://jaxmice.jax.org/protocolsdb/f?p=116:2:3559664766035291::NO:2:P2_MASTER_PROTOCOL_ID,P2_JRS_CODE:4879,003641.
20. Primer3web version 4.0.0 - Pick primers from a DNA sequence. http://bioinfo.ut.ee/primer3.
21. Furukawa K, Clausen H, Hakomori S, Sakamoto J, Look K, Lundblad A, Mattes MJ, Lloyd KO. Analysis of the specificity of five murine anti-blood group A monoclonal antibodies, including one that identifies type 3 and type 4 A determinants. Biochemistry 1985, 24:7820-7826. 10.1021/bi00347a047, 2418872.
22. Dawson G, Stefansson K. Gangliosides of human spinal cord: aberrant composition of cords from patients with amyotrophic lateral sclerosis. J Neurosci Res 1984, 12:213-220. 10.1002/jnr.490120209, 6502751.
23. Rapport MM. Implications of altered brain ganglioside profiles in amyotrophic lateral sclerosis (ALS). Acta Neurobiol Exp (Wars) 1990, 50:505-513.
24. Wu G, Lu ZH, Kulkarni N, Ledeen RW. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res 1997-2008, 2012:90.
25. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 1992, 256:843-846. 10.1126/science.1350379, 1350379.
26. Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci 2013, 324:140-148. 10.1016/j.jns.2012.10.024, 3532888, 23199590.
27. Geisler FH, Dorsey FC, Coleman WP. GM1 gangliosides in the treatment of spinal cord injury: report of preliminary data analysis. Acta Neurobiol Exp (Wars) 1990, 50:515-521.
28. Ohmi Y, Ohkawa Y, Yamauchi Y, Tajima O, Furukawa K. Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem Res 2012, 37:1185-1191. 10.1007/s11064-012-0764-7, 22488331.
29. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, Wang H, Wiznitzer M, Gurtz K, Verganelaki A, Pryde A, Patton MA, Dwek RA, Butters TD, Platt FM, Crosby AH. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 2004, 36:1225-1229. 10.1038/ng1460, 15502825.
30. Boukhris A, Schule R, Loureiro JL, Lourenço CM, Mundwiller E, Gonzalez MA, Charles P, Gauthier J, Rekik I, Acosta Lebrigio RF, Gaussen M, Speziani F, Ferbert A, Feki I, Caballero-Oteyza A, Dionne-Laporte A, Amri M, Noreau A, Forlani S, Cruz VT, Mochel F, Coutinho P, Dion P, Mhiri C, Schols L, Pouget J, Darios F, Rouleau GA, Marques W, Brice A, et al. Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet 2013, 93:118-123. 10.1016/j.ajhg.2013.05.006, 3710753, 23746551.
31. Sokolowski JD, Mandell JW. Phagocytic clearance in neurodegeneration. Am J Pathol 2011, 178:1416-1428. 10.1016/j.ajpath.2010.12.051, 3078427, 21435432.
32. Pekny M, Wilhelmsson U, Bogestål YR, Pekna M. The role of astrocytes and complement system in neural plasticity. Int Rev Neurobiol 2007, 82:95-111.
33. Yanamadala V, Friedlander RM. Complement in neuroprotection and neurodegeneration. Trends Mol Med 2010, 16:69-76. 10.1016/j.molmed.2009.12.001, 2824068, 20116331.
34. Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res 1997, 769:385-390. 10.1016/S0006-8993(97)00849-4, 9374211.
35. Rogers J, Shen Y. A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci 2000, 924:132-135.
36. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 2004, 24:6457-6465. 10.1523/JNEUROSCI.0901-04.2004, 15269255.
37. Fonseca MI, Ager RR, Chu SH, Yazan O, Sanderson SD, LaFerla FM, Taylor SM, Woodruff TM, Tenner AJ. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol 2009, 183:1375-1383. 10.4049/jimmunol.0901005, 19561098.
38. Woodruff TM, Costantini KJ, Taylor SM, Noakes PG. Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors. Adv Exp Med Biol 2008, 632:143-158.
39. Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol 2008, 181:8727-8734.
40. Hoarau JJ, Krejbich-Trotot P, Jaffar-Bandjee MC, Das T, Thon-Hon GV, Kumar S, Neal JW, Gasque P. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol Disord Drug Targets 2011, 10:25-43. 10.2174/187152711794488601, 21143144.
41. Michalek MT, Bremer EG, Mold C. Effect of gangliosides on activation of the alternative pathway of human complement. J Immunol 1988, 140:1581-1587.
42. Ram S, Sharma AK, Simpson SD, Gulati S, McQuillen DP, Pangburn MK, Rice PA. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 1998, 187:743-752. 10.1084/jem.187.5.743, 2212180, 9480984.
43. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004, 15:787-795. 10.1097/01.ASN.0000115702.28859.A7, 14978182.
44. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, . International Registry of Recurrent and Familial HUS/TTP Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279. 10.1182/blood-2005-10-007252, 1895874, 16621965, International Registry of Recurrent and Familial HUS/TTP.
45. Oshima H, Soma G, Mizuno D. Gangliosides can activate human alternative complement pathway. Int Immunol 1993, 5:1349-1351. 10.1093/intimm/5.10.1349, 8268140.
46. Regina Todeschini A, Hakomori SI. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 2008, 1780:421-433. 10.1016/j.bbagen.2007.10.008, 2312458, 17991443.
47. Ohmi Y, Tajima O, Ohkawa Y, Mori A, Sugiura Y, Furukawa K. Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues. Proc Natl Acad Sci U S A 2009, 106:22405-22410. 10.1073/pnas.0912336106, 2792163, 20018737.
48. Ohmi Y, Tajima O, Ohkawa Y, Yamauchi Y, Sugiura Y, Furukawa K. Gangliosides are essential in the protection of inflammation and neurodegeneration via maintenance of lipid rafts: elucidation by a series of ganglioside-deficient mutant mice. J Neurochem 2011, 116:926-935. 10.1111/j.1471-4159.2010.07067.x, 21214571.
49. Pitto M, Mutoh T, Kuriyama M, Ferraretto A, Palestini P, Masserini M. Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons. FEBS Lett 1998, 439:93-96. 10.1016/S0014-5793(98)01344-1, 9849885.
50. Susuki K, Baba H, Tohyama K, Kanai K, Kuwabara S, Hirata K, Furukawa K, Rasband MN, Yuki N. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 2007, 55:746-757. 10.1002/glia.20503, 17352383.
51. Jung WR, Kim HG, Shin MK, Park DI, Kim KL. The effect of ganglioside GQ1b on the NMDA receptor signaling pathway in H19-7 cells and rat hippocampus. Neuroscience 2010, 165:159-167. 10.1016/j.neuroscience.2009.10.012, 19819306.
52. Tajima O, Egashira N, Ohmi Y, Fukue Y, Mishima K, Iwasaki K, Fujiwara M, Sugiura Y, Furukawa K. Dysfunction of muscarinic acetylcholine receptors as a substantial basis for progressive neurological deterioration in GM3-only mice. Behav Brain Res 2010, 206:101-108. 10.1016/j.bbr.2009.09.005, 19744524.
53. McGonigal R, Rowan EG, Greenshields KN, Halstead SK, Humphreys PD, Rother RP, Furukawa K, Willison HJ. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 1944-1960, 2010:133.
54. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178. 10.1016/j.cell.2007.10.036, 18083105.
55. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 2012, 35:369-389. 10.1146/annurev-neuro-061010-113810, 22715882.
56. Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia. Glia 2012, 60:993-1003. 10.1002/glia.22331, 3325361, 22438044.
57. Moriyama M, Fukuhara T, Britschgi M, He Y, Narasimhan R, Villeda S, Molina H, Huber BT, Holers M, Wyss-Coray T. Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J Neurosci 2011, 31:3981-3989. 10.1523/JNEUROSCI.3617-10.2011, 3071463, 21411641.